Cancer vaccines catch ride on UNC-created nanoparticle; Circassia grabs license to microneedle system;

> Research at the University of North Carolina, Chapel Hill found that new nanoparticles could potentially deliver the chemo drug oxaliplatin to tough-to-treat tumors of the colon and pancreas. Item

> A new nanoparticle might offer an efficient and effective delivery vehicle for cancer vaccines. Abstract

> Branching off from its contract-manufacturing roots, SCM Pharma said it is ready to begin its formulation development business with facilities the U.K.-based firm acquired from the University of Sunderland. Release

> NanoPass Technologies has struck a licensing deal with the U.K.'s Circassia that gives Circassia access to NanoPass's microneedle intradermal delivery system for allergy medicines and other therapies. Report

> Allergy Therapeutics has shelled out £600,000 to expand its rights to distribute the Anapen epinephrine pen auto-injector in the U.K. and Ireland. Lincoln Medical's Anapen is used to treat anaphylactic shock. Item

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.